Phaseline

Companies › Eirion Therapeutics

Eirion Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AI-09 Ready Use Injectable Botulinum Toxin
Botulinum toxin type A - cleaves SNARE proteins, blocking acetylcholine release at the neu
SNAREPhase 2Glabellar Lines–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07321834AI-09 Ready Use Injectable Botulinum ToxinPhase 2Glabellar LinesOtherFeb 2026

Targets

SNARE (1)

Companies with the same targets

Vensica Therapeutics

Companies built like this

Ascendis Pharma Endocrinology Division Airway Therapeutics Inotrem Ascendis Pharma Growth Disorders Tego Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.